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Purpose
The biological function of long non-coding RNAs (lncRNAs) is only partially understood; there-
fore, in this study, we investigated the expression of the novel HOXA11 antisense
(HOXA11as) lncRNA and its oncogenic role in serous ovarian cancer (SOC).
Materials and Methods
HOXA11as expression was examined in 129 SOC tissue samples by real time reverse tran-
scription polymerase chain reaction. Clinicopathological factors and patient survival were
compared between the high (n=27) and low HOXA11as expression group (n=102). To 
investigate the role of HOXA11as in cell proliferation, invasion, and migration, HOXA11as
expression in ovarian cancer cells was knocked down using RNA interference.
Results
HOXA11as expression in cancer tissue was 77-fold higher than that of noncancerous tissue
(p < 0.05). Higher HOXA11as expression was significantly correlated with histological grade
(p=0.017) and preoperative cancer antigen 125 (p=0.048). HOXA11as overexpression in
SOC cells led to increased cell proliferation, invasion, and migration. Moreover, HOXA11as
was associated with the expression of genes involved in cell invasion, migration, and 
epithelial-mesenchymal transition (EMT), including vascular endothelial growth factor, matrix
metalloproteinase 9 (MMP-9), B-catenin, E-cadherin, Snail, Twist, and vimentin. Multivariate
analysis revealed that HOXA11as was a prognostic factor of progressive disease and mor-
tality (hazard ratio [HR], 1.730; p=0.043 and HR, 2.170; p=0.033, respectively). Progres-
sion-free and overall survival were significantly shorter in patients with high HOXA11as
expression. 
Conclusion
These findings highlight the clinical significance of HOXA11as to predicting the prognosis
of SOC patients and suggest its potential in promoting tumor aggressiveness via regulation
of vascular endothelial growth factor (VEGF), MMP-9, and EMT-related mechanisms.
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Introduction
Epithelial ovarian cancer has the highest mortality rate
among cancers of the reproductive organs and is the fifth
leading cause of female cancer death in the United States [1].
Despite advances in surgery and chemotherapeutic agents,
the prognosis for ovarian cancer is poor, with a 5-year sur-
vival rate of less than 30% [2]. Serous ovarian cancer (SOC),
which often presents at advanced stages and is characterized
by metastases in the pelvic and abdominal cavity, is the most
common histological type. The poor prognosis of SOC has
been correlated with tumor metastasis and recurrence; there-
fore, it is crucial to understand the underlying molecular
mechanisms involved in ovarian carcinogenesis and progres-
sion.
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Long non-coding RNAs (lncRNAs) comprise a heteroge-
nous group of genomic transcripts longer than 200 
nucleotides that have no protein coding functions [3]. Unlike
short non-coding RNAs such as microRNAs, the functional
role of lncRNAs have been underestimated since they were
initially regarded as transcriptional noise in the genome [4];
however, recent data have demonstrated their importance in
normal physiology, as well as in the modulation of various
biological processes such as cell proliferation, apoptosis, 
invasion, and reprogramming of stem cell pluripotency [4].
Furthermore, emerging evidence indicates that lncRNA 
expression is altered in diverse human cancers, and that its
expression pattern may be associated with cancer progres-
sion and metastasis [5-7].
Members of the homeobox (HOX) family of genes are
known to contain transcription factors that contribute to 
embryogenesis and carcinogenesis [8]. Several studies have
shown dysregulated HOX gene expression in breast, lung,
prostate, and colon cancer [9-13]. In humans, HOX genes are
located in four different chromosomes, organized into four
clusters (A, B, C, and D) [14]. During development of the 
female reproductive tract, HOXA11 is expressed in the cervix
and lower uterine segment; however, its inappropriate 
expression is believed to lead to epithelial ovarian neoplasia
since it promotes aberrant epithelial differentiation [15,16].
Similarly, the HOXA cluster of protein-coding genes con-
tributes to ovarian embryogenesis and carcinogenesis. This
study focused on the ‘antisense’ strand of the HOXA gene
cluster, which contains non-coding RNA genes. The 5' region
of the HOXA locus includes three protein-coding genes
(HOXA9, HOXA10, and HOXA11) and three lncRNAs, HOT-
TIP, HOXA10as (antisense), and HOXA11as. Since little is
known about the function of locally residing lncRNAs, this
study was conducted to investigate the role of HOXA11as in
carcinogenesis.
In this study, the expression of HOXA11as in SOC was 
examined and its clinical significance and correlation to dis-
ease prognosis were analyzed. Functional assays were also
conducted to explore the impact of HOXA11as on cancer cell
invasion and migration in vitro. Finally, since epithelial-mes-
enchymal transition (EMT) is regarded as one of the major
mechanisms inducing cancer metastasis, we investigated
whether HOXA11as was involved in EMT and metastasis in
SOC. 
Materials and Methods
1. Patients and tissue samples
A total of 129 SOC tissue samples were obtained from 
patients who underwent surgery at the Department of 
Factor
HOXA11as expression
p-valueLow High
Age, median±SD (yr) 54.7±11.4 54.6±8.7 0.971
FIGO stage, n (%)
I 6 (5.9) 0 ( 0.463
II 5 (4.9) 0 (
III 68 (66.7) 19 (70.4)
IV 23 (22.5) 8 (29.6)
Histologic grade, n (%)
G1-2 55 (55.6) 8 (29.6) 0.017
G3 44 (44.4) 19 (70.4)
Residual disease, n (%)
Optimal (residual & 1.0 cm) 88 (56.3) 20 (74.1) 0.146
Suboptimal (residual > 1.0 cm) 14 (13.7) 7 (25.9)
Lymph node metastasis, n (%)
Absent 35 (34.3) 10 (37.0) 0.792
Present 67 (65.7) 17 (63.0)
CA125 level (U/mL) 823.1 (4-30,000) 1,599.5 (15-12,000) 0.048
Table 1. HOXA11as expression and clinicopathologic variables in serous ovarian cancer patients (n=129)
HOXA11as, HOXA11 antisense; SD, standard deviation; FIGO, International Federation of Gynecology and Obstetrics; CA125,
cancer antigen 125.
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Obstetrics and Gynecology, Severance Hospital between
April 2003 and December 2013. Patients with borderline
ovarian tumor, concomitant gynecological or other primary
cancer, as well as those who had received preoperative
chemotherapy were excluded. Table 1 summarizes the clin-
ical information describing the patients. The median dura-
tion of follow-up was 39 months (range, 2 to 116 months) for
survivors. Progression-free survival (PFS) was defined as the
interval between the date of surgery and the date of progres-
sion confirmed by imaging studies. Overall survival (OS)
was defined as the date of surgery until the date of death.
The control group consisted of 38 normal ovarian epithelial
tissue samples obtained from patients that underwent simple
hysterectomy or oophorectomy for benign uterine condi-
tions. 
All samples were immediately frozen in liquid nitrogen
and stored at –80°C until RNA extraction. This research was
approved by the Institutional Review Board of Severance
Hospital, Yonsei University College of Medicine (No. 4-2009-
0738), and written informed consent was obtained from
study participants. 
2. Cell line and cell culture
The human epithelial ovarian cancer cell lines OVCAR3
and SKOV3 were obtained from the Korean Cell Line Bank
(KCLB, Seoul, Korea) and the A2780 cell line was purchased
from the European Collection of Cell Cultures (ECACC,
Sigma-Aldrich, St. Louis, MO). Ovarian cancer cell lines
OVCA433, OVCA429, and TOV112D were provided by the
Korea Gynecologic Cancer Bank through the Bio & Medical
Technology Development Program of the Minister of Sci-
ence, Information and Communication Technology and 
Future Planning (MSIP), Korea. Normal human ovarian sur-
face epithelial (HOSE) cells were purchased from ScienCell
Research Laboratories (San Diego, CA). OVCAR3, SKOV3,
and A2780 cells were cultured in RPMI-1640 medium (Gibco-
BRL, Gaithersburg, MD), while OVCA433, OVCA429, and
TOV112D cells were cultured in Dulbecco's modified Eagle
medium and the HOSE cell line was cultured in ovarian 
epithelial cell medium (OEpiCM, ScienCell). All culture
media were supplemented with 10% (vol/vol) fetal bovine
serum and 1% penicillin/streptomycin, and cell lines were
maintained at 37°C in a humidified atmosphere of 5% CO2
and 95% air. Culture medium was replaced with fresh
medium every 2-3 days and cells were used between pas-
sages 5 and 10.
3. Quantitative real-time polymerase chain reaction 
Total RNA was extracted from tissues or cultured cells
using TRIzol reagent (Invitrogen, Carlsbad, CA). For quan-
titative real time polymerase chain reaction (qRT-PCR), total
RNA was reverse transcribed to cDNA using a Reverse Tran-
scription Reagent Kit (Invitrogen) according to the manufac-
turer’s protocols. Real-time PCR analyses were conducted
using a SYBR Green Real-time PCR Kit (TOYOBO Co. Ltd.,
Osaka, Japan). Conditions for the amplification of HOXA11as
lncRNA were as follows: initial denaturation at 95°C for 3
minutes, followed by 40 cycles of denaturation at 95°C for 15
seconds, annealing at 60°C for 60 seconds, and elongation at
72°C for 60 seconds and then final elongation at 72°C for 5
minutes. qRT-PCR was performed using an ABI StepOne-
Plus Real-Time PCR System (Applied Biosystems, Foster
City, CA). The results were normalized to the expression of
U6. The polymerase chain reaction (PCR) primer sequences
used for analyses were as follows: HOXA11as, 5"-GAGTTT-
GAAGCCGTGGATGT-3" (sense) and 5"-AGATGAGGGGA-
GAGGTGGAT-3" (antisense); E-cadherin, 5"-ATTCTGATT-
CTGCTGCTCTTG-3" (sense) and 5"- AGTAGTCATAGTC-
CTGGTCCT-3" (antisense); N-cadherin, 5"-CCCAAGACAA-
GAGACCCAG-3" (sense) and 5"-GCCACTGTGCTTACTG-
AATTG-3" (antisense); !-catenin, 5"-TGCAGTTCG CCTT-
CACTATG-3" (sense) and 5"-ACTAGTCGTGGAATGGCA-
CC-3" (antisense); vimentin, 5"-TGGATTCACTCCCTCTG-
GTT-3" (sense) and 5"-GGTCATCGTGATGCTGAGAA-3"
(antisense); Snail, 5"-GAGGCGGTGGCAGACTAG-3" (sense)
and 5"-GACACATCGGTCAGACCAG-3" (antisense); Twist,
5"-CGGGAGTCCGCAGTCTTA-3" (sense) and 5"-TGAAT-
CTTGCTCAGCTTGTC-3" (antisense); U6, 5"-CTCGCTTCG-
GCAGCACA-3" (sense) and 5"-AACGCTTCAGGAATTTG-
CG T-3" (antisense). The relative change in expression of
mRNA was calculated by the 2–$$CT method. All qRT-PCR
experiments were replicated at least three times.
4. Small interfering RNA transfection 
Homeobox A11 antisense lncRNA small interfering RNA
(siRNA) (siHOXA11as) and negative control siRNA (siNC)
were purchased from Genolution (Genolution Pharmaceuti-
cals Inc., Seoul, Korea). Cells (5"104 cells/well) were seeded
into 6-well plates and transfected with 10 nM siRNA in Opti-
MEM I (Invitrogen) using the Lipofectamine RNAiMAX 
(Invitrogen) according to the manufacturer’s instructions.
These siRNA-transfected cells were used for in vitro assays
48-hour post-transfection. The target sequence for 
siHOXA11as was as follows: siRNA, 5"-CGGAAUAUCG-
GAAUAAAGUUU-3". All experiments were repeated at
least three times.
5. Plasmid constructs and generation of stable cell line
Full-length human HOXA11as transcript cDNA was 
amplified by PCR and inserted into the pLenti6/V5-D-TOPO
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vector according to the ViraPower Lentiviral Expression Sys-
tems (Invitrogen) protocol. Briefly, the plasmid was trans-
fected into 293FT cells for packaging, after which the
lentivirus was used to infect the desired cell lines. The selec-
tion of HOXA11as stably transfected cells was performed in
medium containing 10 µg/mL blasticidin (Invitrogen).
6. Cell proliferation assay 
Cell proliferation was measured by a 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
(Sigma). Briefly, cells (1"104 cells/well) were seeded into 
96-well flat-bottomed plates in 100 µL of complete medium.
The cells were then incubated overnight to allow cell attach-
ment and recovery, after which they were transfected with
siNC or siHOXA11as for 24, 48, 72, or 96 hours. MTT solution
(10 µL) was then added to each well, after which the cells
were incubated for an additional 2 hours. Absorbance was
measured at 570 nm using a microplate reader. Three inde-
pendent experiments were performed in triplicate.
7. Wound healing assay
Cell migration was assessed by monolayer wound healing
assay. Briefly, cells were seeded into 6-well culture plates
with serum-containing medium and allowed to grow to 90%
confluency. The serum-containing medium was then 
removed, after which cells were serum starved for 24 hours.
When the cell confluence reached nearly 100%, an artificial
homogenous wound was created by scratching the mono-
layer with a sterile 200 µL pipette tip. After the cells were
washed with serum-free medium, images of cells migrating
into the wound were captured at 0, 24, and 48/60 hours
using a microscope. Each experiment was repeated three
times.
8. Matrigel invasion assay
Matrigel invasion assay was performed using the BD Bio-
coat Matrigel Invasion Chamber (pore size, 8 µm; 24-well; BD
Biosciences, Bedford, MA) according to the manufacturer's
instructions. Briefly, overexpression cells or siHOXA11as-
transfected cells and siNC-transfected cells (5"104 cells/mL)
were plated in the upper chamber in serum-free medium,
and complete medium was added to the bottom chamber.
After 24 hours of incubation, cells that had invaded through
the membrane were stained using a Differential  Quik Stain
Kit (Diff Quik, Sysmex, Kobe, Japan), then counted using a
light Microscopy Axio Imager M2 (Carl Zeiss, Thornwood,
NY; magnification "200). The assay was performed in tripli-
cate.
9. Western blot analysis 
Proteins were extracted with RIPA buffer (Thermo Fisher
Scientific, Inc., Waltham, MA) and their concentrations were
determined using the Pierce BCA Protein Assay Kit (Thermo
Fisher Scientific). Next, samples were boiled for 5 minutes,
subjected to 10% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis, and transferred electrophoretically to poly-
vinylidene difluoride membranes (Millipore, Billerica, MA).
The membranes were subsequently blocked with 5% non-fat
dried milk in 1" Tris-buffered saline containing 0.1% Tween
20 (TBST; pH 7.6) at room temperature for 1 hour, then incu-
bated with primary antibody at 4°C overnight. Blocked
membranes were then incubated with primary antibodies 
(E-cadherin, N-cadherin, or !-catenin rabbit polyclonal anti-
bodies at final concentrations of 1:1,000, Cell Signaling, Bev-
erly, MA; vimentin, Snail, or !-actin mouse polyclonal
antibodies at a dilution of 1:1,000, Sigma). Primary antibodies
against each protein were detected by horseradish peroxi-
dase-conjugated secondary antibody (1:2,000). Bands were
visualized using a SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific), and band intensities were
quantified using the Luminescent Image Analyzer (LAS-4000
mini, Fujifilm, Uppsala, Sweden). 
10. Data analysis 
Statistical analysis was performed with SPSS ver. 19 for
Windows (SPSS Inc., Chicago, IL). The Kolmogorov-Smirnov
test was used to verify standard normal distributional 
assumptions. A student’s t test and the Mann-Whitney U test
were used for parametric and non-parametric variables, 
respectively. Differences between proportions were com-
pared using Fisher exact test or a chi-square test. PFS and OS
were calculated by the Kaplan-Meier method, while the log-
rank test was used to compare survival distribution. Multi-
variate analysis using the Cox regression model adjusted for
known prognostic covariates (age, stage, tumor grade, lymph
node metastasis, and residual tumor) was conducted. A 
p < 0.05 was regarded as statistically significant. 
Results
1. Expression of HOXA11as is up-regulated in SOC tissues
The expression level of HOXA11as was measured in 129
SOC tissues and 38 corresponding normal ovarian tissues by
qRT-PCR and normalized to U6. HOXA11as expression in
cancer tissue was more than 77-fold higher than that of non-
VOLUME 49 NUMBER 3 JULY 2017  659
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cancerous tissue (p < 0.05) (Fig. 1A). One hundred twenty
nine SOC patients were divided into a high (n=27) and low
expression group (n=102) based on a HOXA11as/U6 ratio of
60 in cancerous tissue (Fig. 1B).
2. Correlation between HOXA11as expression and clinico-
pathological characteristics in SOC
Clinicopathological data such as age, stage, histologic
grade, extent of residual disease, lymph node metastasis, and
preoperative cancer antigen 125 (CA125) level were com-
pared between the high and low HOXA11as expression
groups (Table 1). High grade histology and higher level of
CA125 were more frequently found in the high HOXA11as
expression group (p < 0.05).
3. Downregulation of HOXA11as decreases SOC cell pro-
liferation
To investigate the role of HOXA11as in SOC cells, several
cell lines were examined for HOXA11as expression. As
shown in Fig. 2A, OVCA429, OVCAR3, and SKOV3 
expressed higher levels of HOXA11as than other cell lines
and the control (HOSE). The knockdown efficiency of the
HOXA11as-specific siRNAs (siHOXA11as) was analyzed by
qRT-PCR method, which revealed that siHOXA11as had
higher silencing efficiency compared to control (Fig. 2B). The
proliferation of siHOXA11as-transfected ovarian cancer cells
and siNC was measured by MTT assay. Knockdown of
HOXA11as inhibited cell proliferation by 40% and 50% at 96
hours post-transfection in OVCA429 and SKOV3 cell lines,
respectively, relative to control cells (Fig. 2C and D).
4. HOXA11as attenuates invasion and migration of SOC
cells
The effects of HOXA11as on the invasive and migratory 
behavior of SOC cells were assessed by Matrigel invasion
and wound healing assays. Wound healing assays showed
larger width of wound in siHOXA11as-transfected OVCA
429 and SKOV3 cells than siNC-transfected cells, which
demonstrated decreased migration of SOC cells via down-
regulation of HOXA11as (Fig. 3A and B). According to the
Matrigel invasion assay, the knockdown of HOXA11as sig-
nificantly reduced the invasive cell numbers by more than
80% (Fig. 3C). The same results were obtained from migra-
tion and invasion assays after enforcing HOXA11as expres-
sion in OVCA429 cells (Fig. 3D). The invasive capacity of
OVCA429 cells increased after 48 hours upon overexpression
of HOXA11as (Fig. 3E and F). Taken together, these results
indicate that HOXA11as promotes SOC cell invasion and 
migration in vitro.
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Fig. 1. HOXA11 antisense (HOXA11as) expression in human ovarian tumor tissue. (A) Relative expression of HOXA11as was
significantly higher in serous ovarian cancer (SOC) tissues (n=129) than in noncancerous tissues (n=38). HOXA11as expression
was determined using quantitative real time polymerase chain reaction with U6 as an internal control. (B) HOXA11as
expression was classified into two groups according to the expression level of SOC tissues. Data are expressed as mean±stan-
dard deviation. *p < 0.05 vs. non-tumor control. 
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5. Matrix metalloproteinase and vascular endothelial
growth factor are involved in HOXA11as-related SOC cell
metastasis 
The expression of proteins related to tumor progression
and metastasis were determined in SOC cells to evaluate the
possible mechanism of HOXA11as in cancer cell invasion and
migration. As shown in Fig. 4A, knockdown of HOXA11as
inhibited the level of matrix metalloproteinase (MMP) 2,
MMP-9, and vascular endothelial growth factor (VEGF) 
expression in OVCA429 cells. The expression of these pro-
teins was further validated by western blot analyses, which
showed significantly lower expression in siHOXA11-as
transfected cells than siNC-transfected cells (Fig. 4B). Taken
together, these findings indicate that HOXA11as regulates
SOC cell invasion and migration through the regulation of
MMP and VEGF.
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Fig. 2. Knockdown of HOXA11 antisense (HOXA11as) inhibits serous ovarian cancer cell proliferation. (A) Expression of
HOXA11as in human ovarian surface epithelial cell line (HOSE) and six ovarian cancer cell lines determined by quantitative
real time polymerase chain reaction (qRT-PCR). (B) Knockdown efficiency was determined by qRT-PCR analysis in OVCA429
and SKOV3 cells. Cells were transfected with HOXA11as-specific siRNA (siHOXA11as) and negative control siRNA (siNC).
(C, D) Knockdown of HOXA11as significantly reduced cell proliferation in OVCA429 and SKOV3 cells as determined by 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Bars indicate mean±standard deviation of three
independent experiments performed in triplicate. *p < 0.05 vs. siNC. siHOXA11as, HOXA11as-specific siRNA.
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Fig. 3. HOXA11 antisense (HOXA11as) promotes migration and invasion of ovarian cancer cells. (A, B) Wound healing assay
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(C) Matrigel invasion assay was used to determine invasion after 24 hours in OVCA429 cells. (D) Overexpression of
HOXA11as in OVCA429 cells analyzed by quantitative real time polymerase chain reaction. (E, F) Migration and invasion
assay after overexpressing HOXA11as expression in OVCA429 cells. Overexpression of HOXA11as in OVCA429 cells 
increased the invasive capacity after 48 hours. Each assay was performed in triplicate. Data are mean±standard deviation.
*p < 0.05 vs. siNC, vector. (Continued to the next page)
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6. HOXA11as modulates EMT marker genes in SOC cells
To further investigate the molecular mechanisms involved
in metastatic features of HOXA11as, the EMT marker gene
levels were examined using quantitative PCR and western
blot assays. Epithelial marker E-cadherin was significantly
upregulated and mesenchymal marker N-cadherin, !-catenin,
and vimentin were downregulated in siHOXA11as cells. The
impact of HOXA11as knockdown on the expression of Twist
and Snail, which are known to modulate EMT, was also 
assessed. siHOXA11as-transfected cells showed lower 
expression of Twist and Snail than siNC-transfected cells
(Fig. 5).
7. Higher expression of HOXA11as is correlated with poor
patient survival
The median duration of follow up was 39 months (range,
2 to 116 months). Overall, 45 patients (34.9%) died from the
disease, while 91 (70.5%) had disease recurrence. Survival
analysis was performed to measure the PFS and OS of 
patients with SOC with different HOXA11as expression. As
shown in Fig. 6A, the 10-year PFS of patients who had high
HOXA11as cancer tissue expression was unfavorable relative
to those with low HOXA11as expression (median PFS, 12
months vs. 24 months; p=0.013). Similarly, worse OS out-
comes were shown in the high HOXA11as expression group
than the low expression group (median OS, 53 months vs. 77
months; p=0.045) (Fig. 6B). Furthermore, the receiver oper-
ating characteristic curve analysis showed that the
HOXA11as level was useful to predict survival of SOC 
patients (area under the curve, 0.731; 95% confidence interval
[CI], 0.646 to 0.817) (Fig. 6C). Multivariate Cox regression
analysis for survival revealed that high HOXA11as expres-
sion in tumor tissues was an independent predictor of poor
PFS (hazard ratio [HR], 1.730; 95% CI, 1.015 to 2.948; p=0.043)
and OS (HR, 2.170; 95% CI, 1.062 to 4.431; p=0.033), regard-
less of age, stage, grade, residual tumor size and lymph node
metastasis (Table 2). Upon multivariate analysis for overall
survival, age (HR, 1.044; 95% CI, 1.008 to 1.081; p=0.015) and
residual tumor size of > 1.0 cm (HR, 2.514; 95% CI, 1.223 to
5.167; p=0.012) were associated with mortality, but not with
recurrence. 
Discussion
In this study, HOXA11as expression levels in SOC were
higher than those of noncancerous tissues, and increased
HOXA11as expression was correlated with poor patient sur-
vival. Moreover, knockdown of HOXA11as expression led to
reduced cell proliferation, invasion and migration in SOC
cells. The metastatic effects of HOXA11as were related to the
regulation of genes involved in cell invasion, migration, and
EMT, including VEGF, MMP-9, B-catenin, E-cadherin, Snail,
Twist, and vimentin. These findings highlighted the clinical
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(siNC) for 48 hours. E-cadherin, !-catenin, N-cadherin, vimentin, Snail, and Twist expression were analyzed by quantitative
real time polymerase chain reaction (A) and western blotting (B). Each assay was performed in triplicate. Data are mean±stan-
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relevance of HOXA11as to predicting adverse prognosis of
SOC and suggested its potential in promoting tumor aggres-
siveness via the regulation of VEGF and EMT-related mech-
anisms.
In recent years, accumulating evidence has shown that
lncRNAs may play a critical role in cellular biology and
human diseases. Several lncRNAs have been identified in 
gynecological cancer, including HOTAIR, MALAT-1, H19,
and LSINCT5 [17]. One of the most popular oncogenic
lncRNA studied is HOX transcript antisense intergenic RNA
(HOTAIR), which our group recently identified as playing a
role in cell proliferation and invasion in cervical cancer cell
lines [18]. However, no studies have been published regard-
ing the clinical/prognostic significance of the novel lncRNA
HOXA11as in SOC.
The role of HOXA11as, a novel lncRNA in epithelial ovar-
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ian cancer has been underexplored. In this study, HOXA11as
expression was shown to be higher in cancer tissues, and
knockdown of HOXA11as inhibited cell proliferation in var-
ious ovarian cancer cell lines. Furthermore, overexpression
of HOXA11as in OVCA429 cells enhanced the invasive 
capacity at 48 hours, suggesting that HOXA11as contributes
to the invasive and migratory phenotype of ovarian carci-
noma cells. LncRNAs that are overexpressed in ovarian 
tumors similar to HOXA11as include AB073614, HOST2,
LSINCT5, HOTAIR, and H19 [19-22]. In vitro and in vivo 
observations of these lncRNAs have shown decreased cell
growth, migration, and apoptosis when downregulated as
in this study. Among these, HOST2 has been proposed to
modulate the availability of tumor suppressor that subse-
quently suppresses the expression of targets that regulate cell
growth and motility at the post-transcriptional level [20].
These observations are relevant to HOXA11as because its 
upregulation is similarly associated with cancer cell growth
and migration. To determine if HOXA11as promotes SOC
metastasis by regulating genes that encode certain metasta-
sis-related proteins, the expression of extracellular matrix 
degrading protease MMPs and VEGF were analyzed. MMPs
degrade basement membrane collagen, which promotes
tumor cell invasion and metastasis. These compounds are
also known to decrease survival in several types of cancers
[23]. VEGF, together with MMPs, is known for its role in
tumor angiogenesis and essential for cell motility and metas-
tasis [24]. As expected, our results demonstrated significantly
decreased expression of MMP-2, MMP-9, and VEGF with
downregulation of HOXA11as. These findings indicate that
HOXA11as plays a role in the aggressive nature of ovarian
cancer cells through upregulation of the possible down-
stream targets, MMPs and VEGF.
Since the molecular mechanisms of lncRNAs related to
tumor progression and metastasis are not fully understood,
a question was raised as to whether HOXA11as promotes
SOC metastasis by regulating gene expression that encodes
metastasis-related proteins. One of the possible mechanisms
is thought to be EMT, which involves epithelial cells with
mesenchymal properties such as reduced cell-cell junction
and increased motility. These properties of EMT have been
reported to contribute to cellular proliferation, invasion and
migration in various malignancies [25,26]. The knockdown
of lncRNA HOTAIR was recently shown to be associated
with reversal of the EMT process in gastric cancer cells [27],
and lncRNA MALAT1 was reported to function as an inducer
of EMT in breast cancer by activating the phosphoinositide
3-kinase–AKT pathway [28]. Similarly, genes related to EMT
(E-cadherin, N-cadherin, B-catenin, Snail, and vimentin)
were dysregulated by HOXA11as knockdown in serous type
OVCA429 cells in the present study. Moreover, E-cadherin
was markedly upregulated and the mesenchymal markers
N-cadherin, !-catenin and vimentin were downregulated in
siHOXA11as cells. Furthermore, siHOXA11as-transfected
cells showed lower expression levels of Twist and Snail than
siNC-transfected cells, indicating HOXA11as-mediated reg-
ulation of EMT modulators. Taken together, dysregulated
expression of EMT-related genes appears to take part in
HOXA11as-related SOC cell invasion and migration. 
The results of this study suggest the possible relationship
of HOXA11as with the EMT and contribute to our under-
standing of the role of lncRNAs. Additionally, this is the first
investigation to demonstrate the correlation between the
novel lncRNA HOXA11as and SOC cell metastasis in relation
to EMT. It should be noted that this study was limited by its
retrospective nature; however, a large number of cases were
examined along with long term survival data. Many studies
have shown that lncRNA acts as an unfavorable prognostic
factor in various human cancers [17,18,29]; thus, the clinical
and prognostic significance of HOXA11as were identified in
this study. Moreover, only serous type histology was inves-
tigated to overcome the heterogeneity of the study popula-
tion. Further investigations are required to understand the
role and molecular mechanisms of HOXA11as in other sub-
types of ovarian cancer.
Variable
Progression-free survival Overall survival
HR 95% CI p-value HR 95% CI p-value
Age 1.008 0.987-1.031 0.420 1.044 1.008-1.081 0.015
Stage 1.997 0.180-3.371 0.960 1.120 0.532-2.359 0.765
Histologic grade (grade 1-2 vs. 3) 0.932 0.587-1.479 0.765 0.722 0.379-1.378 0.324
Residual disease (> 1.0 cm vs. & 1.0 cm) 1.678 0.944-2.984 0.078 2.514 1.223-5.168 0.012
LN metastasis (positive vs. negative) 0.795 0.479-1.321 0.376 0.516 0.233-1.141 0.102
HOXA11as expression (high vs. low) 1.730 1.015-2.948 0.043 2.170 1.062-4.431 0.033
Table 2. Multivariate Cox regression model analyses of factors associated with survival
HR, hazard ratio; CI, confidence interval; LN, lymph node; HOXA11as, HOXA11 antisense.
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Conclusion
In summary, HOXA11as was overexpressed in patients
with SOC, and its overexpression was correlated with poor
prognosis. Furthermore, functional studies suggested that
HOXA11as plays a critical role in controlling SOC cell prolif-
eration and invasion via regulation of EMT-related genes.
These findings contribute to a better understanding of dys-
regulated lncRNAs in cancer progression and may provide
guidance for the development of lncRNA-based biomarkers
and precision medicine approaches for treatment of SOC. 
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